Vivek Ramaswamy, the founder of Roivant Sciences, is officially running for president, the GOP hopeful announced Tuesday.
Vivek Ramaswamy/courtesy of Lisa Lake/Getty Images
Vivek Ramaswamy, the founder of Roivant Sciences, is officially running for president, the GOP hopeful announced Tuesday.
“To put America first, we need to rediscover what America is. That’s why I am running for president,” Ramaswamy wrote in a Wall Street Journal editorial. “I am launching not only a political campaign but a cultural movement to create a new American Dream—one that is not only about money but about the unapologetic pursuit of excellence.”
Ramaswamy is a first-generation American entrepreneur and venture capitalist involved in several biotechnology and biopharmaceutical companies. He’s a registered Republican, born and raised in Ohio, according to his website.
As the former CEO of Roivant Sciences, a biopharmaceutical company focused on developing and commercializing innovative therapies for patients, he’s known for his advocacy for the biopharma industry.
“We embrace secular religions like climatism, Covidism and gender ideology to satisfy our need for meaning, yet we can’t answer what it means to be an American,” Ramaswamy wrote in the editorial.
He’s been a vocal advocate for the value biopharma companies bring to the economy and the role of innovation and entrepreneurship in health care and society – topics he’s written about in two books, including, “A Nation of Victims” and “Woke, Inc.: Inside America’s Corporate Social Justice Scam.”
He is also the founder of several other companies in the biopharma space, including Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences and Spirovant Sciences (known as the “vants”).
In 2019, Sumitomo Pharma acquired Roivant’s stakes in some of the subsidiaries for $3 billion.
Ramaswamy is the founder and CEO of Strive Asset Management, a private investment firm focused on investing in growth-stage companies in various industries, including technology, healthcare and consumer products.
The firm’s portfolio includes several familiar names, including Roivant, Myovant and Axovant Sciences.
Ramaswamy earned his bachelor’s degree at Harvard before becoming a biotech investor and hedge fund manager. He earned his law degree at Yale. In the past two years, he’s become a frequent contributor to popular conservative media, such as FOX News Channel and FOX Business.
Ramaswamy plans a campaign stop in Des Moines, Iowa, Thursday. Look to BioSpace for exclusive coverage.
